Your browser is no longer supported. Please, upgrade your browser.
PRFX [NASD]
PainReform Ltd.
Index- P/E- EPS (ttm)- Insider Own23.10% Shs Outstand10.06M Perf Week-13.61%
Market Cap27.47M Forward P/E- EPS next Y-1.50 Insider Trans0.00% Shs Float- Perf Month-37.53%
Income- PEG- EPS next Q-0.56 Inst Own38.93% Short Float- Perf Quarter-41.16%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio0.49 Perf Half Y-40.78%
Book/sh- P/B- EPS next Y26.50% ROA- Target Price- Perf Year-
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range2.62 - 7.85 Perf YTD-38.93%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-65.22% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low4.20% ATR0.34
Employees1 Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)30.09 Volatility10.39% 11.54%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume1.32 Prev Close2.66
ShortableNo LT Debt/Eq- Earnings- Payout- Avg Volume232.57K Price2.73
Recom2.00 SMA20-18.26% SMA50-38.04% SMA200-42.38% Volume307,263 Change2.63%
Mar-18-21 09:15AM  
Mar-11-21 10:43AM  
Mar-08-21 09:00AM  
Jan-07-21 08:30AM  
Jan-06-21 08:30AM  
Jan-04-21 08:30AM  
Nov-23-20 08:30AM  
Nov-12-20 09:00AM  
Nov-05-20 08:30AM  
Oct-19-20 09:00AM  
Sep-29-20 07:30AM  
Sep-09-20 02:15PM  
PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.